PositiveID Clears Final FCC Hurdle to Sell iglucose™ System in US

Share Article

PositiveID Corporation (OTCBB: PSID) a developer of medical technologies for diabetes management and clinical diagnostics, has successfully completed all Federal Communications Commission (“FCC”) required testing for the iglucose™ mobile health device. As a result, the iglucose™ System now meets the regulatory requirements of the FCC to be sold in the U.S.

News Image
Tools and Technology for a Better Life

PositiveID Corporation (OTCBB: PSID) a developer of medical technologies for diabetes management and clinical diagnostics, has successfully completed all Federal Communications Commission (“FCC”) required testing for the iglucose™ mobile health device. As a result, the iglucose System now meets the regulatory requirements of the FCC to be sold in the U.S.. PositiveID also recently received FDA clearance to market the iglucose System in the U.S. The exciting news was additional covered with an informational report of the iglucose System in the American Banking & Market News.

iglucose™ is a mobile health system that seamlessly communicates glucose readings from leading blood glucose meters to the iglucose™ diabetes management portal. From there, this important data can be shared automatically with family members, caregivers and healthcare professionals via text message, email, or fax. iglucose™ eliminates the burden of keeping manual logbooks of glucose levels and empowers people to be more active with the management of their diabetes. Leading diabetes education organizations recommend that people with diabetes check their blood sugar, keep a logbook of their readings, and take them to their healthcare professional. This is a fundamental cornerstone of diabetes management. Unfortunately, many people with diabetes do not keep logbooks. iglucose™ solves this problem by automating the process. iglucose™ not only simplifies life for people with diabetes it also connects them with loved ones and healthcare professionals who are concerned about their care. iglucose™ is truly a “win-win” for all.

Successful passing of all FCC requirements so soon after FDA approval is a true testament to the level of excellence that PositiveID puts into all of their projects and this driving effort will soon result in the iglucose System roll-out into the market place through healthcare insurers and home-healthcare providers in early 2012. This incredible accomplishment to pass all certification testing was also done without the need for any redesigns required considering that all wireless communication devices must pass FCC certification prior to commercial launch, and these mandatory regulatory clearances now position PositiveID to bring iglucose to market to simplify the lives of those individuals and persons connected that have diabetes.

PositiveID Corporation (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems like the Ricin Detection systems noted in the Digital Journal release. PositiveID focuses primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID was recently recommended in a news release by Vista Partners.

For more information please email:
Bonita Dias
info(at)massmedia77(dot)com
T: 770-331-8823
Copyright © 2011 All rights reserved.
PR: http://www.MassMedia77.com Sound Marketing is Smart Business

Safe Harbor Statement:
This report includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2010 and beyond could differ materially from the Company’s current expectations.

Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.

Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of the MyC3 initiative and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with The Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely.

Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.

Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bonita Dias
Visit website

Media